Targeted therapies have represented a tremendous breakthrough in the clinical management of solid malignancies, resulting in reduced adverse side effects and improved clinical outcomes compared with traditional chemotherapy. Since the approval of the first targeting agent tamoxifen in 1970s, 100 monoclonal antibodies and slightly less than 80 kinase inhibitors have been introduced in the clinical practice, leading to new therapeutic possibilities for cancer patients.
Despite undoubtedly huge benefits derived from targeted therapies, advanced tumors inevitably develop strategies to escape target inhibition, leading to drug resistance and disease recurrence. In addition, the growing availability of different therapeutic strategies and their sequential administration in patients affected by advanced malignancy may lead to cross-resistance among sequential drugs. Continuous investigation of the molecular mechanisms that mediate drug resistance and cross-resistance is a challenging issue which requires increasing efforts as new available therapeutic strategies are introduced. In particular, evidences from pre-clinical studies represent a fundamental step for supporting the design of novel combinatorial treatments and effective new molecules that, rapidly moving from bench to bedside, could represent a substantial advantage in term of therapeutic options for oncologic patients.
This research topic aims at providing updates on the molecular underpinnings of resistance to current targeted therapies and cross-resistance in case of sequential treatments in solid malignancies, strategies to overcome it and novel therapeutic strategies. We welcome submissions of Original Research, Clinical Trial, Review and Mini-review articles covering, but not limited to, the following topics:
Molecular mechanisms/genetic alterations involved in resistance/cross-resistance in the field of targeted therapies
Identification of biomarkers predictive of benefit from targeted therapies in solid malignancies
Emergence of novel targetable vulnerabilities under the pressure of targeted therapy
Preclinical and clinical studies proposing innovative approaches to escape resistance/cross-resistance
Novel therapeutic strategies for the treatment of solid malignancies
Design and development of novel small molecules against druggable targets.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Targeted therapies have represented a tremendous breakthrough in the clinical management of solid malignancies, resulting in reduced adverse side effects and improved clinical outcomes compared with traditional chemotherapy. Since the approval of the first targeting agent tamoxifen in 1970s, 100 monoclonal antibodies and slightly less than 80 kinase inhibitors have been introduced in the clinical practice, leading to new therapeutic possibilities for cancer patients.
Despite undoubtedly huge benefits derived from targeted therapies, advanced tumors inevitably develop strategies to escape target inhibition, leading to drug resistance and disease recurrence. In addition, the growing availability of different therapeutic strategies and their sequential administration in patients affected by advanced malignancy may lead to cross-resistance among sequential drugs. Continuous investigation of the molecular mechanisms that mediate drug resistance and cross-resistance is a challenging issue which requires increasing efforts as new available therapeutic strategies are introduced. In particular, evidences from pre-clinical studies represent a fundamental step for supporting the design of novel combinatorial treatments and effective new molecules that, rapidly moving from bench to bedside, could represent a substantial advantage in term of therapeutic options for oncologic patients.
This research topic aims at providing updates on the molecular underpinnings of resistance to current targeted therapies and cross-resistance in case of sequential treatments in solid malignancies, strategies to overcome it and novel therapeutic strategies. We welcome submissions of Original Research, Clinical Trial, Review and Mini-review articles covering, but not limited to, the following topics:
Molecular mechanisms/genetic alterations involved in resistance/cross-resistance in the field of targeted therapies
Identification of biomarkers predictive of benefit from targeted therapies in solid malignancies
Emergence of novel targetable vulnerabilities under the pressure of targeted therapy
Preclinical and clinical studies proposing innovative approaches to escape resistance/cross-resistance
Novel therapeutic strategies for the treatment of solid malignancies
Design and development of novel small molecules against druggable targets.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
